Research Progress in Neoadjuvant Chemotherapy for Bladder Cancer
Neoadjuvant chemotherapy is a systemic pre-operative treatment which can eliminate microscopic lesion of bladder cancer including metastatic lesion. It significantly improves 5-year survival rate of bladder cancer. For patients with non-organ-confined bladder cancer, neoadjuvant chemotherapy combined with radical cystectomy can be a better treatment option. This article covers the current status of bladder treatment and the rise of neoadjuvant chemotherapy, advantages and disadvantages of neoadjuvant chemotherapy, prediction of efficacy of neoadjuvant chemotherapy, the choices for neoadjuvant chemotherapy patient, improvement of neoadjuvant chemotherapy, and large-scale clinical trial of neoadjuvant chemotherapy for bladder cancer.
Witjes JA, Comperat E, Cowan NC, et al., 2014, EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. Eur Urol, 65:778–92. DOI: 10.1016/j.eururo.2013.11.046.
Meeks JJ, Bellmunt J, Bochner BH, et al., 2012, A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol, 62:523–33. DOI: 10.1016/j.eururo.2012.05.048.
International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al., 2011, International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-invasive Bladder Cancer: Long-term Results of the BA06 30894 Trial. J Clin Oncol, 29:2171–7. DOI: 10.1016/j.yuro.2011.06.007.
Kamat AM, Hahn NM, Efstathiou JA, et al., 2016, Bladder Cancer. Lancet, 388:2796–810.
Perlis N, Zlotta AR, Beyene J, et al., 2013, Immediate Post-transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non-muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-evidence Review. Eur Urol, 64:421–30. DOI: 10.1016/j.eururo.2013.06.009.
Froehner M, Koch R, Heberling U, et al., 2016, Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. Eur Urol, 69:984–7. DOI: 10.1016/j.eururo.2015.06.053.
Leow JJ, Martin-Doyle W, Fay AP, et al., 2014, A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma. Eur Urol, 66:529–41. DOI: 10.1016/j.eururo.2014.03.003.
Oddens JR, Sylvester RJ, Brausi MA, et al., 2014, The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-Guerin relative to maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-urinary Group Study 30911. Eur Urol, 66:694–701. DOI: 10.1016/j.eururo.2014.05.033.
Leow JJ, Martin-Doyle W, Rajagopal PS, et al., 2014, Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-analysis of Randomized Trials. Eur Urol, 66:42–54. DOI: 10.1016/j.eururo.2013.08.033.
Sylvester RJ, Oosterlinck W, Holmang S, et al., 2016, Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol, 69:231–44. DOI: 10.1016/j.eururo.2015.07.017.
Jarvinen R, Marttila T, Kaasinen E, et al., 2015, Long-term Outcome of Patients with Frequently Recurrent Non-muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guerin (BCG) or Alternating BCG and Interferon-alpha2b Instillations: Prospective Randomised FinnBladder-4 Study. Eur Urol, 68:611–7. DOI: 10.1016/j.eururo.2015.02.022.
Tarin TV, Power NE, Ehdaie B, et al., 2012, Lymph Node-positive Bladder Cancer Treated with Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity. Eur Urol, 61:1025–30. DOI: 10.1016/j.eururo.2012.01.049.
Milowsky MI, Rumble RB, Booth CM, et al., 2016, Guideline on Muscle-invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol, 34:1945–52. DOI: 10.1200/jco.2015.65.9797.
Sternberg CN, Skoneczna I, Kerst JM, et al., 2015, Immediate Versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol, 16:76–86. DOI: 10.1016/j.eururo.2015.08.013.
Madersbacher S, Hochreiter W, Burkhard F, et al., 2003, Radical Cystectomy for Bladder Cancer Today a Homogeneous Series Without Neoadjuvant Therapy. J Clin Oncol, 21:690–6. DOI: 10.1200/jco.2003.05.101.
Granfors T, Tomic R, Ljungberg B, 2009, Downstaging and Survival Benefits of Neoadjuvant Radiotherapy before Cystectomy for Patients with Invasive Bladder Carcinoma. Scand J Urol Nephrol, 43:293–9.
DOI: 10.1080/00365590902854313.
Rosenblatt R, Sherif A, Rintala E, et al., 2012, Pathologic Downstaging is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Urothelial Bladder Cancer. Eur Urol, 61:1229–38. DOI: 10.1016/j.eururo.2011.12.010.
Galsky MD, Stensland K, Sfakianos JP, et al., 2016, Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. J Clin Oncol, 34:2627–35. DOI: 10.1200/jco.2016.67.5033.